Potential antidepressant LY 367265 presynaptically inhibits the release of glutamate in rat cerebral cortex

Synapse

Volumn 55, Issue 3, 2005, Pages 156-163

  Wang, Su Jane ^a  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Antidepressant; Cerebrocortical synaptosomes; Excitatory neurotransmitter glutamate; Exocytosis

Indexed keywords

1 [2 [4 (6 FLUORO 1H INDOL 3 YL) 3,6 DIHYDRO 1 (2H)PYRIDINYL]ETHYL] 5,6 DIHYDRO 1H,4H [1,25]THIADIAZOLO[4.3.2 IJ]QUINOLINE 2,2 DIOXIDE; 4 AMINOPYRIDINE; GLUTAMIC ACID; IONOMYCIN; IONOPHORE; LY 367265; QUINOLINE DERIVATIVE; SEROTONIN; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CALCIUM TRANSPORT; CONTROLLED STUDY; DEPOLARIZATION; DRUG MECHANISM; FLUOROMETRY; MALE; NERVE ENDING; NERVE EXCITABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPTIC MEMBRANE; SYNAPTOSOME;

4-AMINOPYRIDINE; ANIMALS; ANTIDEPRESSIVE AGENTS; CALCIUM CHANNELS; CALCIUM SIGNALING; CEREBRAL CORTEX; CYCLIC S-OXIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; GLUTAMIC ACID; IONOMYCIN; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE POTENTIALS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PRESYNAPTIC TERMINALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION; SYNAPTOSOMES; THIADIAZOLES;

EID: 13244299244     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20104     Document Type: Article

References (29)

1. Aghajanian GK, Marek GJ. 2000. Serotonin model of schizophrenia: emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31:302-312.
2. 1 receptor inhibition of glutamate exocytosis and protein kinase C-mediated decoupling. J Neurochem 60:1081-1086.
3. Beasley CM, Masica DN, Potvin JH. 1992. Fluoxetine: a review of receptor and functional effects and their clinical implications. Psychopharmacology (Berl) 107:1-10.
4. Choi DW. 1988. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623-634.
5. Danysz W, Parsons AC. 1998. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev 50:597-664.
6. 2(5). Brain Res 462:67-75.
7. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450.
8. Li M, West JW, Numann R, Murphy BJ, Scheuer T, Catterall WA. 1993. Convergent regulation of sodium channels by protein kinase C and cAMP-dependent protein kinase. Science 261:1439-1442.
9. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer HY. 1999. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 19:177-182.
10. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology 28:402-412.
11. Michael-Titus AT, Bains S, Jeetle J, Whelpton R. 2000. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience 100:681-684.
12. Moret C, Briley M. 2000. The possible role of 5-HT1B/D receptors in psychiatric disorders and their potential as a target for therapy. Eur J Pharmacol 404:1-12.
13. Naughton M, Mulrooney JB, Leonard BE. 2000. A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol 15:397-415.
14. Nicholls DG. 1993. The glutamatergic nerve terminal. Eur J Biochem 212:613-631.
15. Nicholls DG, Sihra TS. 1986. Synaptosomes possess an exocytotic pool of glutamate. Nature 32:772-773.
16. Ostroff RB, Nelson JC. 1999. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 60:256-259.
17. 2+ channel coupled to glutamate exocytosis. Eur J Pharmacol 226:343-350.
18. Popoli M, Brunello N, Perez J, Racagni G. 2000. Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J Neurochem 74:21-33.
19. Pullar IA, Carney SL, Colvin EM, Lucaites VL, Nelson DL, Wedley S. 2000. LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone. Eur J Pharmacol 407:39-46.
20. + channels of the mammalian brain. FASEB J 5:164-170.
21. Roeper J, Pongs O. 1996. Presynaptic potassium channels. Curr Opin Neurobiol 6:338-341.
22. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. 2001. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131-134.
23. Sihra TS. 1997. Protein phosphorylation and dephosphorylation in isolated nerve terminals (synaptosomes). In: Hemmings Jr HC, editor. Regulatory protein modification: techniques and protocols. Totowa, NJ: Humana. p 67-119.
24. 2+ entry preferentially effects protein dephosphorylation, phosphorylation, and glutamate release. J Biol Chem 267:1983-1989.
25. Skolnick P. 1999. Antidepressants for the new millennium. Eur J Pharmacol 375:31-40.
26. 2+ and glutamate release. J Neurochem 53:1693-1699.
27. 2+ channels. Synapse 48:170-177.
28. Wong DT, Bymaster FP, Engleman EA. 1995. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57:411-441.
29. Zucker RS. 1993. Calcium and transmitter release. J Physiol 87:25-36.